TXG — 10x Genomics, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1770787 ·
Last close
$47.27
Market Cap
$5.52B
52W High
$50.34
52W Low
$19.82
ADV30
3,164,781
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 150,843,000 | 106,178,000 | -17,046,000 | -13,470,000 | 1,015,759,000 | 490,285,000 | 201,435,000 |
| Dec 2025 | 166,030,000 | 113,045,000 | -19,541,000 | -16,252,000 | 1,041,365,000 | 473,966,000 | 245,039,000 |
| Sep 2025 | 149,002,000 | 100,307,000 | -32,242,000 | -27,472,000 | 1,027,361,000 | 432,508,000 | 242,241,000 |
| Jun 2025 | 172,908,000 | 125,084,000 | -10,574,000 | 34,538,000 | 979,970,000 | 397,712,000 | 206,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,819,000
Investing CF
$-12,856,000
Financing CF
$-2,036,000
CapEx
$-5,639,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,524,061,000
Inventory
$53,487,000
Receivables
$56,137,000
ST Investments
$49,563,000
EBIT TTM
$39,149,000
Pretax Income TTM
$-19,248,000
Interest Exp TTM
$3,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$638,782,976
EBITDA
$-30,669,000
Free Cash Flow
$124,545,128
Enterprise Value
$5,816,985,600
Total Cash
$539,848,000
Total Debt
$81,389,000
Shares Out
116,877,317
Trailing EPS
$-0.18
Book Value
$6.31
ROE
-3.0%
ROA
-4.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,823,000 | -110,885,000 | -43,544,000 | 1,041,365,000 | 245,039,000 | — | 136,050,000 |
| Dec 2024 | 610,785,000 | -194,559,000 | -182,627,000 | 918,636,000 | 208,502,000 | — | 6,664,000 |
| Dec 2023 | 618,727,000 | -204,349,000 | -255,099,000 | 965,143,000 | 224,100,000 | — | -15,197,000 |
| Dec 2022 | 516,409,000 | -167,944,000 | -166,000,000 | 1,028,980,000 | 223,237,000 | — | -33,606,000 |
TTM Snapshot
Revenues TTM
$563,117,000
NetIncome TTM
$-189,968,000
OpCashFlow TTM
$0
Assets (Latest)
$918,636,000
Forward EPS
$0.21
Max Pain — expiry 2026-08-21
max pain strike: $30.00 · spot: $47.27 · call oi: 5,125 · put oi: 1,109
Expected Move to 2026-08-21:
±$8.50
(17.98%) —
implied range
$38.77 –
$55.77
· ATM straddle on $45.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BTDPF | Barratt Developments PLC/ADR | $5.53B | $3.95 | — |
| LPGCY | Laopu Gold Co. Ltd./ADR | $5.53B | $3.85 | — |
| BTDPY | Barratt Developments PLC/ADR | $5.50B | $7.86 | — |
| BLFBY | Balfour Beatty plc/ADR | $5.56B | $23.21 | — |
| RNKGF | RENK Group AG/ADR | $5.49B | $54.89 | — |
News headlines (Yahoo Finance, 1h cache)
1 Surging Stock with Solid Fundamentals and 2 Facing Headwinds
2026-07-31 21:55 · Yahoo
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-07-30 14:00 · Yahoo
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
2026-07-29 13:00 · Yahoo
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
2026-07-29 00:45 · Yahoo
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
2026-07-24 22:49 · Yahoo
Cathie Wood Dumps $39 Million Worth of AMD Stock
2026-07-20 16:06 · Yahoo
1 Cash-Producing Stock with Exciting Potential and 2 Facing Challenges
2026-07-20 13:11 · Yahoo
3 Russell 2000 Stocks We Steer Clear Of
2026-07-16 13:45 · Yahoo
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-15 20:05 · Yahoo
Cathie Wood’s ARK Invest Doubles Down On Circle In Two Funds At Once, Trims Robinhood Again
2026-07-15 11:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.